Literature DB >> 20951699

The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2.

Carmen Chak-Lui Wong1, Chun-Ming Wong, Edmund Kwok-Kwun Tung, Sandy Leung-Kuen Au, Joyce Man-Fong Lee, Ronnie Tung-Ping Poon, Kwan Man, Irene Oi-Lin Ng.   

Abstract

BACKGROUND & AIMS: We investigated mechanisms of hepatocellular carcinoma (HCC) metastasis and identified an antimetastatic microRNA (miRNA), miR-139, that is down-regulated in human HCC samples.
METHODS: Effects of stable and transient expression of miRNA-139 and its inhibitors were studied in the human HCC cell lines SMMC-7721 and BEL7402; cells were analyzed for migration and invasion. Liver samples from patients with metastatic HCC were analyzed for levels of miRNA-139; data were compared with survival data using the Kaplan-Meier method and compared between groups by the log-rank test. Tumor formation and metastasis from human HCC MHCC97L cells that did or did not express miR-139 were analyzed in mice.
RESULTS: Down-regulation of miR-139 in HCC was associated significantly with poor prognosis of patients and features of metastatic tumors, including venous invasion, microsatellite formation, absence of tumor encapsulation, and reduced differentiation. miR-139 expression was reduced in metastatic HCC tumors compared with primary tumors. Overexpression of miR-139 in HCC cells significantly reduced cell migration and invasion in vitro and the incidence and severity of lung metastasis from orthotopic liver tumors in mice. miR-139 interacted with the 3' untranslated region of Rho-kinase 2 (ROCK2) and reduced its expression in HCC cells. Levels of miR-139 were correlated inversely with ROCK2 protein in human HCC samples. Overexpression of miR-139 did not inhibit HCC cell motility when ROCK2 was knocked down.
CONCLUSIONS: The microRNA miR-139 interacts with ROCK2 and reduces its expression in HCC cells. Down-regulation of miR-139 increased the invasive abilities of HCC cells in vitro and HCC metastasis in vivo. Expression of miR-139 is reduced in human metastatic HCC samples and correlates with prognosis.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20951699     DOI: 10.1053/j.gastro.2010.10.006

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  140 in total

1.  Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation.

Authors:  Zhong-Bo Han; Hong-Yuan Chen; Jun-Wei Fan; Jun-Yi Wu; Hua-Mei Tang; Zhi-Hai Peng
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-10       Impact factor: 4.553

2.  Function and clinical potential of microRNAs in hepatocellular carcinoma.

Authors:  Lijuan Wang; Yongfang Yue; Xian Wang; Hongchuan Jin
Journal:  Oncol Lett       Date:  2015-09-29       Impact factor: 2.967

Review 3.  Epigenetics of hepatocellular carcinoma: role of microRNA.

Authors:  Sharad Khare; Qiong Zhang; Jamal A Ibdah
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

Review 4.  Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications.

Authors:  Chun-Ming Wong; Felice Ho-Ching Tsang; Irene Oi-Lin Ng
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-01-10       Impact factor: 46.802

5.  Stat3-mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha.

Authors:  Bo Wang; Shu-Hao Hsu; Wendy Frankel; Kalpana Ghoshal; Samson T Jacob
Journal:  Hepatology       Date:  2012-06-05       Impact factor: 17.425

Review 6.  The role of microRNAs in hepatocarcinogenesis: current knowledge and future prospects.

Authors:  Motoyuki Otsuka; Takahiro Kishikawa; Takeshi Yoshikawa; Motoko Ohno; Akemi Takata; Chikako Shibata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2013-11-21       Impact factor: 7.527

7.  Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status.

Authors:  Lene Rask; Eva Balslev; Rolf Søkilde; Estrid Høgdall; Henrik Flyger; Jens Eriksen; Thomas Litman
Journal:  Cell Oncol (Dordr)       Date:  2014-07-16       Impact factor: 6.730

Review 8.  Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.

Authors:  Behzad Yeganeh; Emilia Wiechec; Sudharsana R Ande; Pawan Sharma; Adel Rezaei Moghadam; Martin Post; Darren H Freed; Mohammad Hashemi; Shahla Shojaei; Amir A Zeki; Saeid Ghavami
Journal:  Pharmacol Ther       Date:  2014-02-26       Impact factor: 12.310

9.  MicroRNA-139 inhibits the proliferation, migration and invasion of gastric cancer cells by directly targeting ρ-associated protein kinase 1.

Authors:  Xuechun Yu; Chaojian Ma; Ling Fu; Jingwu Dong; Jie Ying
Journal:  Oncol Lett       Date:  2018-02-13       Impact factor: 2.967

10.  MicroRNA-148b expression is decreased in hepatocellular carcinoma and associated with prognosis.

Authors:  Zhiyong Zhang; Wei Zheng; Jun Hai
Journal:  Med Oncol       Date:  2014-05-08       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.